Business
HeartBeam (BEAT) Closes $10M Public Offering to Advance Cardiac Technology Commercialization
LOS ANGELES, CA - April 17, 2026 (NEWMEDIAWIRE) - HeartBeam (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses, with the transactio...
About this update from Heartbeam, Inc.
[{"type":"text","content":"LOS ANGELES, CA - April 17, 2026 (NEWMEDIAWIRE) - HeartBeam (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses, with the transaction completed on April 16, 2026. The offering, supported by key stakeholders including ClearCardio(TM), company leadership and institutional investors, will fund commercialization of HeartBeam's FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection technologies, expansion of AI capabilities and general corporate purposes","length":638,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"Investor Brand Network","className":"","disableSlideshowImg":false,"size":{"original":{"width":1352,"height":488,"url":"https://media.zenfs.com/en/newsmediawire_165/6e1352d70061daad28d56e4148cf7a07"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Ty0FB6x_l6kGTOK1ltBdtw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM0Nw--/https://media.zenfs.com/en/newsmediawire_165/6e1352d70061daad28d56e4148cf7a07","width":960,"height":347},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/tkV5OwiIhqibHRt3BAQFzg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04NjY-/https://media.zenfs.com/en/newsmediawire_165/6e1352d70061daad28d56e4148cf7a07","width":1200,"height":433}}},{"type":"text","content":"To view the full press release, visit https://ibn.fm/9iNYY","length":58,"tagName":"p"},{"type":"text","content":"About HeartBeam, Inc.","length":21,"tagName":"p"},{"type":"text","content":"HeartBeam, Inc. is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessme...